Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
This chapter summarizes recent findings regarding the central transmission of acute and chronic itch. Itch is transduced by cutaneous pruriceptors that transmit signals to neurons in the superficial spinal cord. Spinal itch-signaling circuits utilize several neuropeptides whose receptors represent novel targets to block itch transmission. Itch is relieved by scratching, which activates spinal interneurons to inhibit itch-transmitting neurons. Spinal itch transmission is also thought to be modulated by descending pathways. Itch is transmitted rostrally via ascending pathways to activate a variety of brain regions involved in sensory discrimination of affective and motor responses to itch. The pathophysiological mechanisms of chronic itch are poorly understood but likely involve sensitization of itch-signaling pathways and/or dysfunction of itch-inhibitory circuits. Improved understanding of central itch mechanisms has identified a number of novel targets for the development of antipruritic treatment strategies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546762 | PMC |
| http://dx.doi.org/10.1159/000446011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Methods to Validate Digital Health Technologies for Dermatology.
J Invest Dermatol
September 2025
Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Sibel Health, Chicago, Illinois, USA; Querrey Simpson Institute for Bioelectronics, Northwestern University, Evanston, Illinois, USA. Electronic address:
The integration of wearable medical devices and digital health technologies (DHTs) in health care has grown significantly during the past 2 decades, particularly in dermatology, in which objective measurement of symptoms such as itch remains challenging. This review examines the evolution of DHTs in dermatology, focusing on the validation frameworks necessary for their implementation in clinical trials and research. We discuss the key stages of validation: hardware validation to ensure device reliability, analytical validation to transform raw sensor data into meaningful metrics, and clinical validation to demonstrate utility in specific patient populations.
View Article and Find Full Text PDFReal-world effectiveness of lebrikizumab on pruritus in moderate-to-severe atopic dermatitis: preliminary data from a single-center, real-life experience.
Clin Exp Dermatol
September 2025
Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Pharmacokinetics of Ilunocitinib, a New Janus Kinase Inhibitor, in Dogs.
J Vet Pharmacol Ther
September 2025
Elanco Animal Health, Sèvres, France.
Ilunocitinib, a novel Janus kinase inhibitor, is indicated for managing pruritus and skin lesions associated with canine allergic and atopic dermatitis. Pharmacokinetics of ilunocitinib were investigated following single intravenous and oral administrations, both in fed and fasted states. Dose proportionality was assessed using oral doses ranging from 0.
View Article and Find Full Text PDFEtiopathogenesis and Current Management of Oncogenic Pruritus - A Narrative Review.
Indian J Dermatol
September 2025
Department of Dermatology, College of Medicine and Sagore Dutta Hospital, Kolkata, West Bengal, India.
Oncogenic pruritus or malignancy associated pruritus is an emerging cause of systemic pruritus in patients with malignancies. It is a debilitating condition and worsens the patient's quality of life, often interfering with their palliative care. Oncogenic pruritus can arise de-novo in such patients due to release of pruritogens and other inflammatory mediators from tumour cells into blood stream, or it may present as a component of paraneoplastic syndrome.
View Article and Find Full Text PDFFlavonoids in atopic dermatitis: mechanisms, delivery innovations, and translational strategies.
Front Pharmacol
August 2025
School of Chemistry, Chemical Engineering and Biotechnology, Nanyang Technological University, Singapore, Singapore.
Objective: To provide a comprehensive narrative synthesis of recent advances in the pharmacological actions and therapeutic potential of natural flavonoids in atopic dermatitis (AD), with emphasis on their multi-target pharmacological effects across core pathological mechanisms. The review also addresses pharmacokinetic limitations, formulation challenges, delivery innovations, safety concerns, and emerging clinical evidence to inform translational research and therapeutic development.
Methods: This narrative review is based on a targeted literature search of PubMed, Web of Science, ScienceDirect, and SpringerLink, covering English-language, peer-reviewed articles published between 2010 and 2025.